Targeted Oncology

Targeted Healthcare Communications is at the forefront of the increasing interest in cancer-related products within precision medicine. We proudly hold the distinction of being the first publisher to feature a peer-reviewed journal dedicated to these innovative products. Our offerings include a specialized website, two journals, and a variety of multichannel programs that all concentrate on precision medicine in the field of oncology. Our publication, Targeted Therapies in Oncology™, is committed to equipping oncology healthcare professionals with the latest research, data, and treatment methods related to molecular and immune system targets that can enhance patient outcomes in cancer care. We aim to make the latest developments in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted treatments more accessible for clinical application. The Journal of Targeted Therapies in Cancer™ focuses on elevating cancer patient care by publishing peer-reviewed clinical articles that delve into advancements in cancer targets and targeted therapies, along with their practical applications. Our goal is to broaden oncologists' understanding of biomarkers, pathways, diagnostics, immunotherapy, and targeted therapies, while also providing strategies for personalizing treatment to achieve better patient outcomes. TargetedOnc.com™ is a distinctive resource that emphasizes molecular biology, featuring expert insights on research, management, and treatment. This oncology-centered website is dedicated to providing content that highlights precision medicine in the field. As cancer research shifts towards systems biology and molecular irregularities, many oncologists face the challenge of keeping their knowledge up to date with the evolving landscape of cancer therapeutics.

International, National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#339713

United States

#144675

Health/Health Conditions and Concerns

#337

Traffic sources

Monthly visitors

Articles

Navigating the Transformation of AI Cancer Detection and Diagnosis

1 day ago | targetedonc.com | Dylann Cohn-Emery

Read the first half of the interview here. In an interview with Targeted OncologyTM, Stuart J.
BOND/CORE-001: uGDB as a Biomarker for Viral Therapy in Bladder Cancer

4 days ago | targetedonc.com | Jordyn Sava

Key findings from updated analyses of the BOND-003 and CORE-001 trials (NCT04452591; NCT04387461), presented by Colin P.N. Dinney, MD, PhD, demonstrate the clinical utility of urinary genomic disease burden (uGDB), assessed via the UroAmp platform, in predicting response to cretostimogene grenadenorepvec therapy for bladder cancer.1 The UroAmp assay, a convergent genomic and genetic liquid biopsy, quantifies mutations and DNA alterations in urine tumor DNA to determine minimal residual...
First-Line Disitamab Vedotin/Toripalimab Shows Benefit in HER2+ la/mUC

4 days ago | targetedonc.com | Jordyn Sava

Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) benefits were seen with disitamab vedotin (RC48) in combination with toripalimab-tpzi (Loqtorzi) vs standard chemotherapy when used as a first-line treatment for patients with HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC), meeting the 2 primary end points of the phase 3 RC48-C016 trial (NCT05302284).1 Compared with the strongly positive findings of a...
Steroid Therapy for cGVHD

4 days ago | targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy

Treatment Approaches (Part 1) For newly diagnosed moderate to severe cGVHD, the panel discussed: Initial steroid dosing: Dr Bishop: 1 mg/kg/day for severe cases, possibly split dosing Dr Shaughnessy: 0.5 mg/kg/day for many cases, 1 mg/kg/day for severe lung or liver involvement All agree on assessing response for at least 1-2 weeks before tapering Steroid taper considerations: Slow, cautious tapers, especially for cGVHD (unlike acute GVHD) Generally 10 mg every 1-2 weeks after stabilization,...
A 50-Year-Old-Woman With cGVHD

4 days ago | targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy

Clinical Case Presentation (Part 1)A 50-year-old woman underwent allogeneic transplant with reduced-intensity conditioning from a matched unrelated donor for mesenchymal stromal cells. Her donor was a cytomegalovirus-negative 45-year-old man, and GVHD prophylaxis was tacrolimus and mycophenolate mofetil.
The Oncology Community Faces Unusual Uncertainty

6 days ago | targetedonc.com | Robert Ferris

The field of cancer research and treatment is, almost by definition, continually evolving. That progress has come with uncertainties and irregular leaps of progress. There are also periods of disappointment and stagnation, when the standard of care doesn’t change, right up to the point when it leaps ahead with innovative discoveries and survival benefits based on remarkably creative and effective new diagnostics or treatments.
FDA Clears IND for Novel DLL3-Targeted ADC in Solid Tumors

6 days ago | targetedonc.com | Sabrina Serani

The FDA has cleared the investigational new drug (IND) application for IDE849 (SHR-4849) in solid tumor treatment. IDE849 is a first-in-class delta-like ligand 3 (DLL3) topoisomerase-I (TOP1) antibody-drug conjugate (ADC). With this clearance, a phase 1 study (NCT06443489) will begin. The IND for the first-in-class ADC IDE849 has been cleared by the FDA, paving the way for a phase 1 study to investigate the agent in solid tumors.
Durvalumab Plus BCG Improves Survival in Early Bladder Cancer

1 week ago | targetedonc.com | Jordyn Sava

Treatment with the combination of durvalumab (Imfinzi) and standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy led to a statistically significant and clinically meaningful improvement in disease-free survival (DFS) when used for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) vs BCG induction and maintenance therapy alone, according to high-level data from the phase 3 POTOMAC trial (NCT03528694).1 While the study was not...
NCCN Adds Naxitamab to Practice Guidelines for High-Risk Neuroblastoma

1 week ago | targetedonc.com | Sabrina Serani

Naxitamab-gqgk (Danyelza) has been added to the National Comprehensive Cancer Network’s (NCCN) Clinical Practice Guidelines in Oncology as a Category 2A treatment for high-risk neuroblastoma.1“We are very pleased with NCCN’s update of the NCCN Guidelines to include naxitamab-gqgk.
AI-Powered Pathology Tools May Boost Precision Oncology

1 week ago | targetedonc.com | Dylann Cohn-Emery

Artificial intelligence (AI) could revolutionize cancer diagnostics by improving accuracy, efficiency, and workflow, while also handling tedious tasks. However, its adoption will depend on the technology and accessibility at individual institutions and practices. “AI will ever replace pathologists [or oncologists], but it's the next new technology that pathologists will employ to help them make better, more accurate diagnoses,” Stuart J. Schnitt, MD, said in an interview with Targeted Oncology.